Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)view on SAM.gov

Agency: Department of the Army Office: Army Contracting Command, Edgewood Contracting Division Location: Fort Detrick, MD, USA Program Office: Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRN Defense), Joint Project Lead Enabling Technologies (JPL ET) RPP Number: W911SR-26-R-CADENCC Date Issued: 03 September 2026 Proposals Due: 1500 hours, 17 September 2026 1. Through this Request for Project Proposal (RPP), the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense's (CPE CBRN Defense) Joint Project Lead Enabling Technologies (JPL ET) seeks to develop Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC), an enabling capability that will accelerate clinical trial startup through implementation of Master Protocols, innovative technologies that support decentralized trial operations and augment data collection and analysis, and establishment of a pre-positioned clinical trial site network enabling CBRN defense readiness as described in the attached Statement of Objectives (SOO). The Government is hereby requesting formal submission of preproposals to execute a formal agreement under 10 USC 4022, Other Transaction Authority (OTA) for the prototype project described below. Upon receipt of a preproposal submitted in response to this RPP, the next steps are as follows: The Government will evaluate the preproposal. Discussions among the parties, whether verbally or in writing, will occur as appropriate. The Government may request a full proposal from the offeror. Additional discussions will occur as necessary. Award may be made after evaluation and selection of a successful submission. (Note: Awards are dependent upon the availability of funds.) 2. This RPP is issued to request project proposals in compliance with USC 4022 and is being issued for planning purposes only. It is not to be construed as a commitment by the Government to award an agreement, nor will the Government pay for the information solicited. 3. The JPL ET enables the rapid development, manufacture, and fielding of safe and effective medical solutions across the full product spectrum, including development, clinical trials, manufacturing, and validated biological threat detection materials. The objective of Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC) is to develop an enabling capability that will accelerate clinical trial startup through implementation of Master Protocols, innovative technologies that support decentralized trial operations and augment data collection and analysis, and establishment of a pre-positioned clinical trial site network enabling CBRN defense readiness. CADENCC will primarily conduct Phase I/Phase II clinical trials for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and early treatment products which may be under Animal Rule.…